DOCSLIB.ORG

Viewer Blinded to Treatment Allocation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Viewer Blinded to Treatment Allocation CLINICAL RESEARCH www.jasn.org A Trial of Extending Hemodialysis Hours and Quality of Life † ‡ | Meg J. Jardine,* Li Zuo, Nicholas A. Gray ,§ Janak R. de Zoysa ,¶ †† Christopher T. Chan ,** Martin P. Gallagher ,* Helen Monaghan,* ‡‡ | †††† Stuart M. Grieve , §§ Rajesh Puranik, ¶¶ Hongli Lin,*** Josette M. Eris , ‡‡‡ |||||| Ling Zhang, Jinsheng Xu,§§§ Kirsten Howard, ¶¶¶ Serigne Lo,* Alan Cass,**** and †††† Vlado Perkovic,* on behalf of the ACTIVE Dialysis Steering Committee *The George Institute for Global Health, ††Concord Clinical School, ‡‡Sydney Translational Imaging Laboratory, Charles Perkins Centre, Sydney Medical School, and ||||||School of Public Health, University of Sydney, Sydney, Australia; †Department of Renal Medicine, Concord Repatriation General Hospital, Sydney, Australia; ‡Department of Nephrology, Peking University People’s Hospital, Beijing, China; §Department of Renal Medicine, Nambour General Hospital, Nambour, Australia; |Sunshine Coast Clinical School, The University of Queensland, Brisbane, Australia; ¶Department of Nephrology, North Shore Hospital, University of Auckland, Auckland, New Zealand, **Division of Nephrology, University Health Network, Toronto, Canada; Departments of §§Radiology, |Cardiology, and †††Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ¶¶Specialist Magnetic Resonance Imaging, Newtown, Australia; ***First Affiliated Hospital of Dalian Medical University, Dalian, China; ‡‡‡Department of Nephrology, China-Japan Friendship Hospital, Beijing, China; §§§Fourth Hospital Affiliated to Hebei Medical University, Shijiazhuang, China; ¶¶¶Institute for Choice, University of South Australia, Sydney, Australia; ****Menzies School of Health Research, Charles Darwin University, Darwin, Australia; and ††††Department of Renal Medicine, Royal North Shore Hospital, Sydney, Australia ABSTRACT The relationship between increased hemodialysis hours and patient outcomes remains unclear. We randomized (1:1) 200 adult recipients of standard maintenance hemodialysis from in-center and home-based hemodialysis programs to extended weekly ($24 hours) or standard (target 12–15 hours, maximum 18 hours) hemodialysis hours for 12 months. The primary outcome was change in quality of life from baseline assessed by the EuroQol 5 di- mension instrument (3 level) (EQ-5D). Secondary outcomes included medication usage, clinical laboratory values, vascular access events, and change in left ventricular mass index. At 12 months, median weekly hemodialysis hours were 24.0 (interquartile range, 23.6–24.0) and 12.0 (interquartile range, 12.0–16.0) in the extended and standard groups, respectively. Change in EQ-5D score at study end did not differ between groups (mean difference, 0.04 [95% confidence interval, 20.03 to 0.11]; P=0.29). Extended hours were associated with lower phosphate and potassium levels and higher hemoglobin levels. Blood pressure (BP) did not differ between groups at study end. Extended hours were associated with fewer BP-lowering agents and phosphate-binding medications, but were not associated with erythropoietin dosing. In a substudy with 95 patients, we detected no difference between groups in left ventricular mass index (mean difference, 26.0 [95% confidence interval, 214.8 to 2.7] g/m2;P=0.18). Five deaths occurred in the extended group and two in the standard group (P=0.44); two participants in each group withdrew consent. Similar numbers of patients experienced vascular access events in the two groups. Thus, extending weekly hemodialysis hours did not alter overall EQ-5D quality of life score, but was associated with improvement in some laboratory parameters and reductions in medication burden. (Clinicaltrials.gov identifier: NCT00649298). J Am Soc Nephrol 28: 1898–1911, 2017. doi: https://doi.org/10.1681/ASN.2015111225 Outcomes for patients receiving maintenance dial- Received November 12, 2015. Accepted November 28, 2016. ysis are poor, with mortality rates many times Published online ahead of print. Publication date available at greater than the general population1 and a substan- www.jasn.org. 20 tially reduced quality of life. The rise in mortality Correspondence: Prof. Meg Jardine, The George Institute for and cardiovascular events as kidney function falls,3 Global Health, PO Box M201, Missenden Road, NSW 2050, with amelioration after renal transplantation,4 has Australia. Email: [email protected] driven the hypothesis that increasing dialysis Copyright © 2017 by the American Society of Nephrology 1898 ISSN : 1046-6673/2806-1898 JAmSocNephrol28: 1898–1911, 2017 www.jasn.org CLINICAL RESEARCH exposure will improve outcomes for people with kidney group (Figure 2). First treatment commenced a mean of 37.4 failure. Observational studies from several countries5–9 have (median, 27) days after randomization in the extended group supported this hypothesis and suggest a strong relationship and 24.2 (median, 15) days in the standard group. between weekly dialysis hours and survival. The few random- An estimate of small molecule clearance, predominantly ized studies assessing increasing dialysis hours have suggested urea reduction ratio, was available in 152 (75.1%) participants improvements in a number of surrogate outcomes, but have also according to usual site practices (Supplemental Table 3) and raised concerns about possible adverse effects on dialysis vascu- included measures conducted within the 3-month time win- lar access,10 residual renal function,11 and long-term mortality.12 dow for baseline assessment in 117 participants (Supplemen- Quality of life is substantially worse in patients receiving tal Table 4). The mean urea reduction ratio, the measured dialysis compared with the general population,13 whereas in- single pool Kt/V, and the calculated standardized Kt/V were creased weekly dialysis hours are associated with better quality greater in the extended group than the standard group at each of life in observational studies; however, recent trials have not postrandomization assessment (average difference of 7.1% clearly defined the effects of dialysis hours on this outcome.14,15 [95% confidence interval (95% CI), 4.9 to 9.3; P,0.001], The presence and magnitude of any benefit is central to the 0.48 [95% CI, 0.27 to 0.68; P,0.001], and 1.29 [95% CI, assessment of cost-effectiveness for quality of life outcomes, 0.61 to 1.96; P=0.001], respectively). such as quality-adjusted life years, as extending dialysis hours increases treatment costs in most settings.16 Outcomes Quality of Life Objective In the extended dialysis hours group, quality of life assessed by Weaimed to conduct a prospectiverandomizedtrial to evaluate EQ-5D at 12 months decreased by 0.018, as compared with the effect of increasing weekly hemodialysis hours on quality 0.055 in the standard group (between-group difference at study of life over 12 months compared with standard hemodialysis. endadjustedforbaseline:0.037;95%CI,20.03 to 0.11; P=0.33; Figure 3, Supplemental Figure 1). The results were similar for the prespecified subgroup analyses defined by re- RESULTS gion, dialysis location, and dialysis vintage (Figure 4, P het- erogeneity all .0.2). In addition, no effect from increased Patients dialysis hours was seen when EQ-5D scores from all follow-up From 2009 to 2013, 200 participants were randomized from 40 visits throughout the intervention period were considered sites. Baseline characteristics were similar across randomized using a linear mixed model (mean difference, 0.03 [95% CI, groups (Table 1). Treatment was discontinued before 12 20.03 to 0.09]; P=0.30), in the sensitivity analyses excluding months in 16 participants because of death (seven partici- participants who did not complete an end of study quality pants), transplantation (five participants), and withdrawal of of life assessment (mean difference, 0.03; 95% CI, 20.04 to consent (four participants) (Figure 1). Analyzable results from 0.10; P=0.33), or in the post hoc sensitivity analysis adjusted the EuroQol 5 dimension instrument (3 level) (EQ-5D) qual- for baseline presence of chronic heart failure, diabetes, di- ity of life assessments were performed in 195 participants, alysis vintage, or catheter use (mean difference, 0.03; 95% excluding the four who withdrew consent, and one who de- CI, 20.04 to 0.01; P=0.36). There was no suggestion of clined to answer one part of the questionnaire at baseline. trend in the evolution of quality of life scores (Supplemental Figure 2). Delivered Treatment There was a small but statistically significant improvement Median weekly dialysis hours received were doubled in the in the Physical Component Summary (PCS) score with ex- extended group (median, 24 hours; interquartile range tended hours, but no effect on Mental Component Summary [IQR], 24–24 hours) compared with standard group (median, (MCS) score of the 36-Item Short Form Health Survey (SF-36) 12 hours; IQR, 12–16 hours) at 12 months, which was pre- quality of life measure in the prespecified analysis from baseline dominantly achieved by longer treatment sessions rather than to 12 months (between-group difference at 12 months adjusted increased session frequency (Table 2). Both blood and dialysis for baseline: 2.68 [95% CI, 0.39 to 4.97; P=0.02] and 1.53 flow rates were lower in the extended group (Supplemental [95% CI, 21.17 to 4.23; P=0.27], respectively). Both PCS Table 1). Most patients were treated with high flux, synthetic and MCS significantly improved with extended hours when membranes (Supplemental Table 2). No participant was treated
Load more

Recommended publications
  • Our Mission Is to Improve the Health of Millions of People Worldwide
    Our mission is to improve the health of millions of people worldwide The George Institute for Global Health 2014–15 Annual Report “I am The George because I’m passionate about healthcare research.” Mohammed Alim, Research Fellow, The George Institute, India The George Institute for Global Health ABN 90 085 953 331. We are a registered charity in Australia and the United Kingdom. George Clinical Pty Ltd ABN 33 098 184 528. All amounts are in Australian dollars unless otherwise indicated. Annual Report Production Team: E. Richard Mills, Director, Global Communications and Advocacy. Maya Kay, Communications Manager Australia. Chelsea Hunnisett, Communications & Events Coordinator, Australia Communications. Alexander Baldock, Design Manager, Global Communications and Advocacy. The George Institute for Global Health 2 2014-15 Annual Report Who we are Established in 1999, The George Institute for Global Health is a global, not-for-profi t medical research organisation, affi liated with leading academic partners, with major centres in Australia, China, India and the United Kingdom. We have been ranked among the top 10 research institutions in the world for scientifi c impact by the SCImago Institutions Rankings (SIR) World Reports in 2011, 2012, 2013 & 2014. Our mission Our Mission is to improve the health of millions of people worldwide. Our VALUES Our humanitarian commitment Our focus on excellence will Our integrity will underpin all our will spur us to tackle the health produce scientifi c evidence work and interactions, including issues affecting high-risk and that is ethical and of the our collaborations with partner disadvantaged people worldwide. highest quality. organisations worldwide.
    [Show full text]
  • Screening for Latent Tuberculous Infection in People Living with HIV Infection in Auckland, New Zealand
    INT J TUBERC LUNG DIS 21(9):1008–1012 Q 2017 The Union http://dx.doi.org/10.5588/jtld.17.0103 Screening for latent tuberculous infection in people living with HIV infection in Auckland, New Zealand N. Gow, S. Briggs, M. Nisbet Department of Infectious Diseases, Auckland City Hospital, Auckland, New Zealand SUMMARY SETTING: New Zealand, which has a low incidence of RESULTS: Of the 752 patients from the initial cohort, tuberculosis (TB), has historically taken a risk-based 416 (55%) had documentation of LTBI screening, which approach to screening for latent tuberculous infection was positive in 74 (10%): 19/461 (4%) low-risk and 55/ (LTBI) in adult people living with the human immuno- 291 (19%) high-risk patients. LTBI treatment was deficiency virus infection (PLHIV). received in 13 low-risk and 44 high-risk patients. Of OBJECTIVE: To evaluate LTBI screening, treatment and 73 patients in the second cohort, 68 (93%) were outcomes in an adult PLHIV population. screened. DESIGN: This was a retrospective clinical record review CONCLUSION: LTBI screening was incomplete in our of an initial cohort of adult PLHIV attending the clinic, but improved between 2011 and 2014. A Auckland City Hospital HIV clinic in 2011, and a significant number of patients with LTBI did not second cohort of adult PLHIV newly attending the clinic originate from a high TB incidence country. in 2014. We analysed high-risk (born in or acquiring KEY WORDS: PLHIV; high-income countries; screen- HIV in a high TB incidence country) and low-risk ing; IGRA patients using descriptive statistical methods.
    [Show full text]
  • Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study
    CLINICAL RESEARCH www.jasn.org Chronic Kidney Disease, Cardiovascular Events, and the Effects of Perindopril-Based Blood Pressure Lowering: Data from the PROGRESS Study Vlado Perkovic,*† Toshiharu Ninomiya,* Hisatomi Arima,* Martin Gallagher,* Meg Jardine,* Alan Cass,*‡ Bruce Neal,* Stephen MacMahon,*‡ and John Chalmers*‡ *George Institute for International Health, University of Sydney, †Royal North Shore Hospital, and ‡Royal Prince Alfred Hospital, Sydney, Australia ABSTRACT Chronic kidney disease (CKD) is associated with a high risk of cardiovascular disease, but evidence regarding the effectiveness of interventions to reduce that risk is lacking. The Perindopril Protection against Recurrent Stroke Study (PROGRESS) study enrolled 6105 participants with cerebrovascular disease and randomly allocated them to perindopril-based blood pressure–lowering therapy or placebo. Individuals with CKD were at approximately 1.5-fold greater risk of major vascular events, stroke, and coronary heart disease, and were more than twice as likely to die (all PՅ0.002). Perindopril-based treatment reduced the risk of major vascular events by 30% and stroke by 35% among subjects with CKD, and the absolute effects of treatment were 1.7-fold greater for those with CKD than for those without. Considering patients with CKD and a history of cerebrovascular disease, perindopril prevented one stroke or other cardiovascular event among every 11 patients treated over five years. In conclusion, kidney function should be considered when determining the need for blood pressure lowering therapy in patients with cerebrovascular disease. J Am Soc Nephrol 18: 2766–2772, 2007. doi: 10.1681/ASN.2007020256 Chronic kidney disease (CKD) is being increasingly monly elevated in people with CKD, raising the recognized as a leading public health problem.
    [Show full text]
  • New Zealand Out-Of-Hospital Acute Stroke Destination Policy Northland and Auckland Areas
    New Zealand Out-of-Hospital Acute Stroke Destination Policy Northland and Auckland Areas This policy is for the use of clinical personnel when determining the destination hospital for patients with an acute stroke in the out-of-hospital setting in the Northland and Auckland areas of New Zealand. It has been developed by the Northern Region Stroke Network in conjunction with the National Stroke Network and the Ambulance Sector. Publication date October 2020 Acute Stroke Destination Flowchart: Auckland Area Does the patient have signs or symptoms Stroke is unlikely, treat of an acute stroke? NO appropriately without YES using this policy. Perform additional screening using the PASTA tool Will the patient arrive at: NO NO A stroke hospital within 4 hours Does the patient Transport to the of symptom onset, or meet ‘wake-up’ most appropriate Auckland City Hospital within stroke criteria?1 hospital. 6 hours of symptom onset? YES YES Transport to the catchment YES PASTA positive? NO area hospital and notify hospital personnel of the Patient will arrive in ED 0800–1600, Mon–Fri following information: PASTA results and Transport to the most appropriate stroke hospital and notify hospital personnel as below: FAST results and Time of symptom onset and North Shore Hospital. Auckland City Hospital. NHI number Waitakere Hospital. Middlemore Hospital. Out of hours If the patient is in the North Shore Hospital, Notify hospital personnel Waitakere Hospital or Middlemore Hospital ASAP and provide the catchment: following information as a – Phone the on-call neurologist at Auckland City minimum: Hospital on 0800 1 PASTA as per the PASTA tool.
    [Show full text]
  • Effects of Fibrates in Kidney Disease a Systematic Review and Meta-Analysis
    Journal of the American College of Cardiology Vol. 60, No. 20, 2012 © 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.049 Effects of Fibrates in Kidney Disease A Systematic Review and Meta-Analysis Min Jun, BSC(HONS), MSC(CLINEPI),* Bin Zhu, MD, PHD,† Marcello Tonelli, MD, PHD,‡ Meg J. Jardine, MBBS, PHD,* Anushka Patel, MBBS, PHD,* Bruce Neal, MB, CHB, PHD,* Thaminda Liyanage, MBBS,§ Anthony Keech, MBBS, MSC (EPID),ʈ Alan Cass, MBBS, PHD,* Vlado Perkovic, MBBS, PHD* Sydney, Australia; Hangzhou, China; and Edmonton, Alberta, Canada Objectives The purpose of this systematic review and meta-analysis was to determine the efficacy and safety of fibrate therapy in the chronic kidney disease (CKD) population. Background Fibrate therapy produces modest cardiovascular benefits in people at elevated cardiovascular risk. There is lim- ited evidence about the clinical benefits and safety of fibrate therapy in the CKD population. Methods MEDLINE, EMBASE, and the Cochrane Library were systematically searched (1950 to January 2012) for prospec- tive randomized controlled trials assessing the effects of fibrate therapy compared with placebo in people with CKD or on kidney-related outcomes were included. Results Ten studies including 16,869 participants were identified. In patients with mild-to-moderate CKD (estimated glo- merular filtration rate [eGFR] Յ60 ml/min/1.73 m2), fibrates improved lipid profiles (lowered total cholesterol [Ϫ0.32 mmol/l, p ϭ 0.05] and triglyceride levels [Ϫ0.56 mmol/l, p ϭ 0.03] but not low-density lipoprotein cho- lesterol [Ϫ0.01 mmol/l, p ϭ 0.83]; increased high-density lipoprotein cholesterol [0.06 mmol/l, p ϭ 0.001]).
    [Show full text]
  • Community to Hospital Shuttle Service
    Is other transport assistance Total Mobility Scheme available? The Total Mobility Scheme is a subsidised taxi Best Care for Everyone Yes, there are several options available to those service. The scheme is available to people who qualify. who are unable to use public transport due to the nature of their disability. It works using vouchers that give a 50% discount on normal National Travel Assistance (NTA) Policy taxi fares. The scheme is part-funded by the NTA helps with travel costs for people who New Zealand Transport Agency and managed need to travel often or for long distances to get by the local authorities. to specialist health or disability services. The MAXX Contact Centre can provide the To receive this service, you need to be referred contact details for disability agencies that by your specialist (not your family doctor) to process applications. Call 09 366 6400 see another specialist or to receive specialist services. Both the specialists must be part of a St John Health Shuttle - Waitakere service funded by the government. The St John Health Shuttle provides safe, For example, this could be a renal dialysis reliable transport for Waitakere City residents centre, a specialist cancer service or a child to and from appointments with family doctors, development service. The rules are different treatment at Waitakere Hospital outpatient for children and adults, and for those holding clinics, visits to specialists, and transport to a Community Services Card. Sometimes, a and from minor day surgery. The vehicle is support person can receive assistance too. wheelchair accessible. The service operates Monday to Friday for appointments between How do I contact NTA? 9.30am and 2pm.
    [Show full text]
  • Initial Experience with Dabigatran Etexilate at Auckland City Hospital
    THE NEW ZEALAND MEDICAL JOURNAL Journal of the New Zealand Medical Association CONTENTS This Issue in the Journal 4 A summary of the original articles featured in this issue Editorial 7 A call for collaboration on inflammatory bowel disease in New Zealand Russell Walmsley Original Articles 11 The cost of paediatric and perianal Crohn’s disease in Canterbury, New Zealand Michaela Lion, Richard B Gearry, Andrew S Day, Tim Eglinton 21 Screening for Mycobacterium tuberculosis infection among healthcare workers in New Zealand: prospective comparison between the tuberculin skin test and the QuantiFERON-TB Gold In-Tube® assay Joshua T Freeman, Roger J Marshall, Sandie Newton, Paul Austin, Susan Taylor, Tony C Chew, Siobhan Gavaghan, Sally A Roberts 30 Audit of stroke thrombolysis in Wellington, New Zealand: disparity between in-hours and out-of-hours treatment time Katie Thorne, Lai-Kin Wong, Gerard McGonigal 37 Training medical students in Pacific health through an immersion programme in New Zealand Faafetai Sopoaga, Jennie L Connor, John D Dockerty, John Adams, Lynley Anderson 46 Insomnia treatment in New Zealand Karyn M O’Keeffe, Philippa H Gander, W Guy Scott, Helen M Scott 60 Evaluation of New Zealand’s bicycle helmet law Colin F Clarke 70 Sun protection policies and practices in New Zealand primary schools Anthony I Reeder, Janet A Jopson, Andrew Gray Viewpoint 83 Should measurement of vitamin D and treatment of vitamin D insufficiency be routine in New Zealand? Mark J Bolland, Andrew Grey, James S Davidson, Tim Cundy, Ian R Reid NZMJ 10 February 2012, Vol 125 No 1349; ISSN 1175 8716 Page 1 of 126 http://journal.nzma.org.nz/journal/125-1349/5068/ ©NZMA Clinical Correspondence 92 A case of yellow fever vaccine-associated disease Heather Isenman, Andrew Burns 96 An unusual cause of carotid sinus hypersensitivity/syndrome Donny Wong, Joey Yeoh 99 Medical image.
    [Show full text]
  • Run Description
    RUN DESCRIPTION POSITION: Registrar Cardiology Catheterization Laboratory DEPARTMENT: Cardiology PLACE OF WORK: North Shore Hospital RESPONSIBLE TO: Clinical Director Medicine, Clinical Director of Cardiology, Cardiology Services Manager FUNCTIONAL Health Care Consumers, multidisciplinary healthcare team RELATIONSHIPS: PRIMARY OBJECTIVE: • To play an active role in performance and reporting of cardiac catheterization procedures performed at CVU in collaboration with Specialist Consultant. • To play an active role in outpatient clinics and cardiology service in collaboration with specialist consultant • To participate as an active member of the team promoting effective management of the cardiology patients. • To provide a high standard of clinical practice and clinical expertise in the assessment, investigation, diagnosis and treatment of patients. • To provide supervision, instruction and support for junior medical staff. • To provide after hours on-call duties covering medical patients. RUN RECOGNITION: The run is accredited for the training of basic and advanced Cardiology trainees RUN PERIOD 6 months Section 1: Registrar Responsibilities Area Area Clinical Duties & CardioVascular Unit Duties Work Schedule • The CardioVascular unit at North Shore Hospital performs diagnostic coronary angiography, angioplasty and cardiac pacing procedures for a population of in excess of 500,000 channelled through North Shore and Waitakere Hospitals. It is a newly established facility commissioned in November 2008. Around 150 coronary procedures are performed every month in addition to around 15 pacing procedures. There are 2 full-time interventional cardiologists, a 0.2 FTE part-time interventionist seconded from Auckland City Hospital and 5 general cardiologists performing diagnostic coronary studies. There is 0.5FTE interventional fellow availability. WDHB Cardiology Cath Lab Registrar Run Description – Effective 12 December 2011 Disclaimer: Please note that this run description is current at time of publication, however this information can be subject to change.
    [Show full text]
  • Proceedings of the Waikato Clinical Campus Biannual Research Seminar Wednesday 11 March 2020
    PROCEEDINGS Proceedings of the Waikato Clinical Campus Biannual Research Seminar Wednesday 11 March 2020 Ablation of ventricular patients (inability to locate PVC Pain relief options in arrhythmias at origin in a patient with multiple labour: remifentanil different morphologies, inad- Waikato Hospital vertent aortic puncture with no PCA vs epidural Janice Swampillai,1 E Kooijman,1 M sequelae, PVC focus adjacent to Dr Jignal Bhagvandas,1 Symonds,1 A Wilson,1 His bundle, cardiogenic shock Mr Richard Foon2 1 1 1 RF Allen, K Timmins, A Al-Sinan, during anaesthesia). Endo- 1Whangarei Hospital, Whangarei; D Boddington,2 SC Heald,1 MK Stiles1 cardial ablation was done in 96 2Waikato Hospital, Hamilton. 1Waikato Hospital, Hamilton; patients and three patients also Objective 2Tauranga Hospital, Tauranga. underwent epicardial ablation Remifentanil is commonly Background (one patient underwent two used in obstetrics due to its Catheter ablation can be an epicardial procedures including fast metabolism time. It is effective treatment strategy one open chest procedure). an attractive option for IV for patients with ventricular General anaesthesia was used patient-controlled analgesia tachycardia (VT) or frequent in 46% of cases, conscious (PCA) in labour. We compared premature ventricular sedation was used in 54%. the effi cacy of IV Remifen- complexes (PVCs). The goal is to Sixty-two percent were elective tanil PCA with epidural during improve quality of life as well as procedures and 38% were labour. mortality. done acutely. The overall acute Method success rate was 91%, falling to Objectives Using a retrospective We aimed to characterise 75% at three months, 73% at six approach, we identifi ed a our population of patients who months and 68% at 12 months.
    [Show full text]
  • Bloodstream Infection with Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae at a Tertiary Care Hospital in New Zeal
    International Journal of Infectious Diseases 16 (2012) e371–e374 Contents lists available at SciVerse ScienceDirect International Journal of Infectious Diseases jou rnal homepage: www.elsevier.com/locate/ijid Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes a, b c d Joshua T. Freeman *, Stephen J. McBride , Mitzi S. Nisbet , Greg D. Gamble , a e b Deborah A. Williamson , Susan L. Taylor , David J. Holland a Department of Clinical Microbiology, LabPlus, PO Box 110031, Auckland City Hospital, Auckland 1148, New Zealand b Department of Medicine, Middlemore Hospital, Auckland, New Zealand c Department of Infectious Diseases, Auckland City Hospital, Auckland, New Zealand d Department of Biostatistics, University of Auckland, Auckland, New Zealand e Department of Clinical Microbiology, Middlemore Hospital, Auckland, New Zealand A R T I C L E I N F O S U M M A R Y Article history: Objectives: To define local risk factors and outcomes for bacteremia with extended-spectrum beta- Received 26 July 2011 lactamase-producing Enterobacteriaceae (ESBL-E) at a tertiary hospital in New Zealand. Received in revised form 30 November 2011 Methods: Patients with ESBL-E bacteremia were compared to matched control patients with non-ESBL- Accepted 11 January 2012 producing Enterobacteriaceae bacteremia. Patients were matched by onset of bacteremia (community vs. Corresponding Editor: Karamchand Ramo- hospital), site of blood culture collection (peripheral vs. via central line), and infecting organism species. tar, Ottawa, Canada Results: Forty-four cases with matched controls were included. Eight- and 30-day mortality was higher in cases than controls (27% vs.
    [Show full text]
  • ADHB Neurology House Officer Run Description
    RUN DESCRIPTION POSITION: HOUSE OFFICER DEPARTMENT: Neurology PLACE OF WORK: Auckland City Hospital RESPONSIBLE TO: Business Manager Neuroservices through the Clinical Director Neurology and Clinical Neurophysiology Service FUNCTIONAL Healthcare consumer, Hospital and community based healthcare workers RELATIONSHIPS: PRIMARY OBJECTIVE: To facilitate the management of patients under the care of the Neurology Service. RUN RECOGNITION: Recognised as Category B for the purposes of registration by the Medical Council of New Zealand RUN PERIOD: 3 months Section 1: House Officer’s Responsibilities Area Responsibilities General Facilitate the management of inpatients commensurate with and appropriate to the house officer’s skill level; Manage the assessment and admission of acute and elective patients under the care of his/her team. Undertake clinical responsibilities as directed by the Registrar or Consultant, also organise relevant investigations, ensure the results are followed up, sighted and electronically signed; Be responsible, under the supervision of the Registrar and/or Consultant, to review inpatients on a daily basis (with the exception of unrostered weekends); Plan and deliver active anticancer treatment (as directed) Maintain a high standard of communication with patients, patients’ families and staff; Inform registrars/consultants of the status of patients especially if there is an unexpected event; Liaise with other staff members, departments, and General Practitioners in the management of in-patients; Communicate with patients and (as appropriate) their families about patients’ illness and treatment Prepare required paperwork on Friday prior to known or likely weekend discharges. Attend handover, Team and departmental meetings as required. ADHB Neurology House Officer Run Description- Effective 25 November 2013 Disclaimer: Please note that this run description is current at time of publication, however this information can be subject to change.
    [Show full text]
  • Hand Surgery Fellowships
    HAND SURGERY FELLOWSHIPS VICTORIA Victorian Hand Surgery Associates Fellowship A Fellowship in hand surgery is available for a 6 or 12 month period for surgeons who have successfully completed their basic surgical training and are interest in furthering their training in hand surgery. The successful candidate will work with the surgeons of the Victorian Hand Surgery Associates in private practice and with the Plastic and Hand Surgery Units of St.Vincent’s Public Hospital in Melbourne. The fellowship involves pre-operative management of a wide variety of hand conditions. These would include elective and emergency conditions including microsurgery reconstruction and replantation. Some exposure to paediatric hand surgery is available with visits to the Royal Children’s Hospital. The candidate would be expected to be involved in the day to day running to the hand service including undergraduate and post-graduate teaching, journal club, audit meetings, clinical and radiology conferences and ongoing clinical research. The candidate would also attend regular meetings of the Victorian Hand Surgery Society. A monthly stipend is available for unfunded fellows. For further details, interested candidates should contact: Mr A.Berger Suite 1 Level 3 Healy Wing St.Vincent’s Public Hospital 41 Victoria Parade Fitzroy 3065 Victoria Australia Email: [email protected] Hand Surgery Fellowship position at Dandenong Hospital Applications are invited for a Hand Surgery Fellowship position at Dandenong Hospital, Southern Health, Melbourne. This position is suitable for a candidate preparing for a career in hand surgery. The successful candidate will be involved in emergency and elective cases, oncall from the emergency department and outpatient care.
    [Show full text]